Celularity Inc
CELUW
12 hedge funds and large institutions have $47.8K invested in Celularity Inc in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
77% more capital invested
Capital invested by funds: $27K → $47.8K (+$20.9K)
10.17% more ownership
Funds ownership: 1.42% → 11.58% (+10%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8% less funds holding
Funds holding: 13 → 12 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$189 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$3.11K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311 |
| 3 |
CS
Clear Street
New York
|
-$7 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2 |
CELUW Hedge Fund Activity: Q4 2024 in Review
12 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celularity Inc (CELUW) for Q4 2024, worth a combined $47.8K — up 77% from $27K a quarter earlier.
Fund positioning in CELUW was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $189. The largest seller was Walleye Capital, cutting an estimated $3.11K.
- 12 institutional investors held Celularity Inc (CELUW) as of Q4 2024, down from 13 in Q3 2024.
- Funds reported $47.8K of Celularity Inc stock for Q4 2024, up 77% quarter-over-quarter.
- 2 funds opened new Celularity Inc positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Celularity Inc buyer in Q4 2024 was Two Sigma Securities, an estimated $189 added.
- The largest Celularity Inc seller in Q4 2024 was Walleye Capital, an estimated $3.11K sold.
Based on aggregated 13F filings for Q4 2024.